- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
December 10th, 2007
Arch Venture Partners, the 21-year-old venture capital firm whose Seattle area investments include Allozyne, Trubion Pharmaceuticals and VLST, has raised a $400 million venture fund.
It is the firm's seventh fund. The money will be invested in early-stage companies in the biotechnology, advanced materials, nanotechnology and semiconductor sectors.
|Related News Press|
BESSTECH Announces $250K Investment from Eastern New York Angels : Funding will accelerate commercialization of BESSTECH’s innovative lithium-ion battery electrode technology and enable hiring of key personnel May 13th, 2015
Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015
Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015
Haydale Named Lead Sponsor for Cambridge Graphene Festival May 22nd, 2015